U09.9
Conditions
Interventions
Group 1: Following intranasal insulin administration, participants will undergo functional magnetic resonance imaging (fMRI) at rest and during performance of a reward task, as well as phosphorus and
Sponsors
AG Neurometabolic Circuitry, Klinik für Psychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Frankfurt, Goethe Universität
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Control group: • Age:18-65 years • BMI: 20-40 kg/m2 • Ability to give informed consent Patients: • Age:18-65 years • BMI: 20-40 kg/m2 • Ability to give informed consent • Medical diagnosis of Post- or Long-Covid documented by a physician prior to study inclusion • Persistent or new symptoms after acute infection that interfere with daily activity > 4 weeks • Depression (BDI-II >11) or fatigue (MFIS >38)
Exclusion criteria
Exclusion criteria: Control and patient groups: • History of psychiatric, neurological, autoimmune, rheumatological, neoplastic, dermatological, metabolic disease except insulin resistance • Acute infection • Pregnancy and nursing
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Alterations in reward-related brain activity (fMRI) and central metabolism (MRS) after intranasal insulin administration compared with placebo in Long-Covid patients with and without insulin resistance relative to the control group. | — |
Secondary
| Measure | Time frame |
|---|---|
| Alterations in reward learning between groups, associations between metabolic status and neuropsychiatric symptoms, and changes in mood, fatigue, and subjective state in Long-Covid patients in relation to insulin resistance compared to the control group. | — |
Countries
Germany
Contacts
Public ContactSharmili Edwin Thanarajah
AG Neurometabolic Circuitry, Klinik für Psychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Frankfurt, Goethe Universität
Outcome results
None listed